ClinicalTrialsFinder

FGFR2 Genetic Alterations Clinical Trials in Philadelphia, Pennsylvania

1 recruitingPhiladelphia, Pennsylvania

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316